The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | CTCs in CSF could predict response and prognosis in leptomeningeal disease
Mark Jeng, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes findings from a study examining circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) as a prognostic and predictive biomarker in leptomeningeal disease. A higher initial CTC burden predicted poorer survival and when tracking CTC levels over time, patients who had a decrease in CTCs after treatment with proton craniospinal irradiation experienced a longer central nervous system progression-free survival. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
